The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry.
 
Michael Ong
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Novartis / AAA; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; Merck; Pfizer/EMD Serono; Sanofi
Research Funding - AstraZeneca (Inst); BMS (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen
 
Soumyajit Roy
Employment - Artera (I); Rush University
Stock and Other Ownership Interests - Merck; Pfizer
Honoraria - Specialty Networks
Research Funding - Prostate Cancer Foundation; Swim Across America
 
Kim Chi
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BMS GmbH & Co. KG; BMS GmbH & Co. KG; Janssen; Merck; Novartis; Pfizer; POINT Biopharma; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BMS GmbH & Co. KG; Janssen; Merck; POINT Biopharma; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Tanya Dorff
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Novartis; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Hookipa Biotech (Inst); Janssen Oncology (Inst); Promontory Therapeutics (Inst)
 
Sebastien Hotte
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Scientific and Medical Affairs Inc; Bayer
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Merck; Novartis Canada Pharmaceuticals Inc; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst); SignalChem (Inst)
 
Alexander Wyatt
Honoraria - AstraZeneca; Bayer; Janssen; Merck; Pfizer
Research Funding - ESSA (Inst); Promontory Therapeutics (Inst); Tyra Biosciences (Inst)
 
Lauren Howard
Consulting or Advisory Role - Tempus
 
Karen Autio
Honoraria - MashupMedia
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Janux Therapeutics (Inst); Pfizer (Inst)
 
Deborah Enting
Speakers' Bureau - Ipsen; Janssen Oncology; Merck; Pfizer
Travel, Accommodations, Expenses - MSD
 
Aurelius Omlin
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen (Inst); Molecular Partners (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Speakers' Bureau - Advanced accelerator; Astellas Pharma; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen-Cilag; Janssen-Cilag (Inst)
Research Funding - Janssen (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; Sanofi
 
Joaquin Mateo
Consulting or Advisory Role - Amunix; AstraZeneca; Daiichi Sankyo Europe GmbH; Illumina; MSD; Nuage Therapeutics; Pfizer
Speakers' Bureau - AstraZeneca; Guardant Health; Janssen; Pfizer
Research Funding - Amgen (Inst); AstraZeneca (Inst); Pfizer (Inst)
Other Relationship - Nuage Therapeutics
 
Raymond McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Ian Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); ESSA (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
(OPTIONAL) Uncompensated Relationships - ANZUP Cancer Trials Group
 
Anders Bjartell
Stock and Other Ownership Interests - Glactone Pharma; Lidds; WntResearch
Consulting or Advisory Role - Accord Healthcare; Astellas Pharma; AstraZeneca; Bayer; IPSEN; Janssen-Cilag; Pfizer
Speakers' Bureau - Astellas Pharma; Ipsen; Janssen-Cilag
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Ferring (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Laurel Cannon
No Relationships to Disclose
 
Alyssa Chan-Cuzydlo
No Relationships to Disclose
 
Philip Kantoff
Employment - Convergent Therapeutics
Leadership - Context Therapeutics; Convergent Therapeutics; ESSA
Stock and Other Ownership Interests - Candel Therapeutics; Context Therapeutics; PrognomIQ; SynDevRx
Consulting or Advisory Role - Candel Therapeutics; Context Therapeutics; OncoCellMDX; PrognomIQ; SynDevRx
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent)
Other Relationship - Bayer (I)
 
Lorelei Mucci
Employment - Convergent Therapeutics (I)
Leadership - Context Therapeutics (I); Essa (I)
Stock and Other Ownership Interests - Context Therapeutics (I); Convergent Therapeutics; Essa (I)
Consulting or Advisory Role - Bayer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
 
Daniel George
Leadership - Capio BioSciences
Stock and Other Ownership Interests - Pfizer
Honoraria - American Association for Cancer Research; Astellas Pharma; AstraZeneca; Aveo; Axess Oncology; Bayer; Eisai; EMD Serono; Exelixis; IDEOlogy Health; Janssen Oncology; Merck; Millennium Medical Publishing; Myovant Sciences; Novartis; OncLive; Pfizer; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Exelixis; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Novartis; Pfizer; Physicans' Education Resource
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Expert Testimony - Exelixis
Travel, Accommodations, Expenses - Bayer; Exelixis; Merck; Novartis; Pfizer